Marker Therapeutics (NASDAQ:MRKR) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Marker Therapeutics (NASDAQ:MRKR) issued its quarterly earnings data on Friday. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02, FiscalAI reports. The firm had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%.

Marker Therapeutics Stock Down 2.7%

MRKR stock traded down $0.04 during midday trading on Friday, hitting $1.42. 28,062 shares of the company traded hands, compared to its average volume of 74,933. Marker Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.07. The stock has a market capitalization of $23.67 million, a price-to-earnings ratio of -1.67 and a beta of 1.43. The business has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $1.43.

Hedge Funds Weigh In On Marker Therapeutics

A number of institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. raised its position in shares of Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after purchasing an additional 13,340 shares during the period. Renaissance Technologies LLC boosted its holdings in Marker Therapeutics by 16.4% during the fourth quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock valued at $184,000 after acquiring an additional 17,400 shares during the period. Jane Street Group LLC bought a new stake in Marker Therapeutics during the second quarter valued at about $33,000. LPL Financial LLC boosted its holdings in Marker Therapeutics by 41.7% during the fourth quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock valued at $124,000 after acquiring an additional 24,500 shares during the period. Finally, Virtu Financial LLC bought a new stake in Marker Therapeutics during the third quarter valued at about $25,000. Institutional investors own 22.39% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Marker Therapeutics currently has an average rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.